What is Rezolute?
Rezolute is a biopharmaceutical company dedicated to disrupting current treatment paradigms by developing novel therapies for devastating rare and chronic metabolic diseases. Its innovative approach integrates patient, clinician, and advocate voices into the drug development process, aiming to significantly improve outcomes and reduce the treatment burden for patients and healthcare systems. The company's lead clinical asset, RZ358, is in late-stage development for congenital hyperinsulinism, a rare pediatric endocrine disorder. Additionally, Rezolute is advancing RZ402, an orally available plasma kallikrein inhibitor, for the treatment of diabetic macular edema. This strategic focus positions Rezolute to make a profound, positive, and lasting impact on patients' lives.
How much funding has Rezolute raised?
Rezolute has raised a total of $117.4M across 4 funding rounds:
Debt
$1.4M
Share Placement
$45M
Private Equity
$41M
Debt
$30M
Debt (2013): $1.4M, investors not publicly disclosed
Share Placement (2019): $45M led by Genexine, Inc. and Handok, Inc.
Private Equity (2020): $41M supported by BVF Partners L.P., Federated Hermes Kaufmann, Surveyor Capital, and CAM Capital
Debt (2021): $30M featuring SLR Capital
Key Investors in Rezolute
BVF Partners L.P.
BVF Partners L.P. is an investment firm that has participated in Rezolute's funding rounds.
Federated Hermes Kaufmann
Federated Hermes Kaufmann is an investment entity that has provided backing to Rezolute.
Surveyor Capital
Surveyor Capital, a division of Citadel, is known for its quantitative investment strategies and has invested in Rezolute.
What's next for Rezolute?
With substantial enterprise-level backing, Rezolute is poised to accelerate the development and potential commercialization of its pipeline assets, particularly RZ358 and RZ402. The recent major strategic investment signals strong confidence from investors in the company's therapeutic approach and market potential. Future endeavors will likely focus on advancing RZ358 through late-stage trials and potentially bringing RZ402 to market, addressing critical unmet needs in rare and chronic metabolic diseases. This capital infusion will be instrumental in navigating regulatory pathways and scaling operations to meet anticipated demand.
See full Rezolute company page
